Avatar 1Avatar 2Avatar 3Avatar 4Avatar 5

Earn 10$ Cash for every Pro+ Friend you Refer!

AD

ADC Therapeutics SA

ADCT · NYSE
ADCT · NYSE

Next Earnings: 05 May 2025

3.72
USD0.339.73%

Latest News

    @eWhispers
    eWhispers

    Bigger-than-usual #earnings moves today from $CAR $CHGG $CEIX $ANET $HSC $UAA $ADCT $SABR $CVI $NBIX $BWXT $SKT $EXTR $GPN $IAA $LXU $LGIH $IART https://t.co/1pgojKC5HH https://t.co/LEKBqjsqAA

      @eWhispers
      eWhispers

      #earnings before the open tomorrow https://t.co/lObOE0dgsr $PFE $CRSR $BP $UAA $COP $GNRC $EPD $RACE $EL $MPC $LPX $ARCB $GPN $CTLT $RL $BLMN $MPLX $IDXX $NRZ $CMI $BHC $ZBRA $IT $MGY $ESPR $DD $KKR $APO $ETN $AME $MIME $ADCT $ROK $TECH $INCY $LIND $BCC $SAGE $LGIH $IEP $LEA https://t.co/3WJfl37gq5

      Analysts Recommendations

      Bullish

      Buy

      Strong Buy

      Buy

      Hold

      Sell

      Strong Sell

      Day Range

      3.06USD
      3.72USD

      52 Week Range

      0.98USD
      6.04USD

      Market Cap

      310.37MUSD

      About

      General Information

      Type

      Common Stock

      Exchange

      NYSE

      Currency Code

      USD

      Currency Name

      US Dollar

      Country Name

      USA

      Country ISO

      US

      ISIN

      CH0499880968

      CUSIP

      Sector

      Healthcare

      Industry

      Biotechnology

      Fiscal Year End

      December

      IPO date

      -

      Updated At

      -

      Highlights

      PE Ratio

      -

      PEG Ratio

      -

      Book Value

      -1.78

      Dividend Share

      -

      Dividend Yield

      -

      Earnings Share

      -2.39

      Wall Street Target Price

      8.4

      EPS Estimate Current Year

      0

      EPS Estimate Next Year

      0

      EPS Estimate Current Quarter

      -0.39

      EPS Estimate Next Quarter

      -0.39

      Most Recent Quarter

      -

      Profitability

      Revenue TTM

      70,717,000

      Gross Profit TTM

      35,098,000

      EBITDA

      -136,868,000

      Profit Margin

      -300.00%

      Return On Assets TTM

      -21.17%

      Return On Equity TTM

      -705.53%

      Revenue Per Share TTM

      0.774

      Qtly Revenue Growth YOY

      27.40%

      Diluted Eps TTM

      -2.39

      Qtly Earnings Growth YOY

      0.00%

      Valuation

      Trailing PE

      0.00

      Forward PE

      0

      Price Sales TTM

      4.7581

      Price Book MRQ

      2.5787

      Enterprise Value Revenue

      2

      Enterprise Value EBITDA

      -1

      Peers analysis

      • CSL Limited
        CMXHFCSL Limited

        178.29

        4.66%
      • BioNTech SE
        BNTXBioNTech SE

        118.68

        1.68%
      • Alnylam Pharmaceuticals Inc
        ALNYAlnylam Pharmaceuticals Inc

        255.10

        0.52%
      • argenx SE
        ARGNFargenx SE

        525.60

        0.00%
      • BeiGene Ltd
        BGNEBeiGene Ltd

        189.37

        -8.70%
      • UCB SA ADR
        UCBJYUCB SA ADR

        94.73

        -1.46%
      • CSL Ltd
        CSLLYCSL Ltd

        89.92

        -0.81%
      • argenx NV ADR
        ARGXargenx NV ADR

        609.88

        -0.50%
      • Regeneron Pharmaceuticals Inc
        REGNRegeneron Pharmaceuticals Inc

        775.00

        -0.45%
      • Vertex Pharmaceuticals Inc
        VRTXVertex Pharmaceuticals Inc

        468.95

        -0.13%